SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

SAN

85.83

+0.01%↑

MRK1

115.45

-0.04%↓

ARGX

783.2

-1.01%↓

PHIA

24.23

-0.29%↓

ONC.US

339.45

-0.35%↓

Search

Vetoquinol SA

Closed

SectorHealthcare

72.6 0.28

Overview

Share price change

24h

Current

Min

71.7

Max

72.6

Key metrics

By Trading Economics

Income

-9.8M

25M

Sales

-17M

258M

P/E

Sector Avg

14.177

79.874

Dividend yield

1.26

Profit margin

9.734

Employees

2,497

EBITDA

-12M

48M

Dividends

By Dow Jones

Dividend yield

Sector Avg

1.26%

2.31%

Market Stats

By TradingEconomics

Market Cap

-54M

855M

Previous open

72.32

Previous close

72.6

News Sentiment

By Acuity

50%

50%

168 / 374 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Bearish Evidence

Vetoquinol SA Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

27 lis 2025, 16:49 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks to Buy Fund-Tech Platform Allfunds in $6 Billion Deal

27 lis 2025, 15:32 UTC

Acquisitions, Mergers, Takeovers

TotalEnergies, Repsol in Talks to Combine U.K. North Sea Assets, Cinco Dias Says, Citing Sources

27 lis 2025, 23:50 UTC

Market Talk

Nikkei May Trade Rangebound Amid Caution Over Economic Outlook -- Market Talk

27 lis 2025, 23:50 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

27 lis 2025, 16:05 UTC

Market Talk

Canadian Job Vacancies Rise for Fist Time Since Start of 2024 -- Market Talk

27 lis 2025, 16:04 UTC

Market Talk

Canadian Payroll Employment Pulls Back in September, Offsetting Recent Gains -- Market Talk

27 lis 2025, 15:54 UTC

Acquisitions, Mergers, Takeovers

Allfunds Shares Rise 21% After Deutsche Boerse Says Started Acquisition Talks

27 lis 2025, 15:44 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: No Certainty Talks Will Result in Transaction

27 lis 2025, 15:43 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Allfunds Board of Directors Has Agreed to Enter Exclusive Talks

27 lis 2025, 15:42 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse: Nonbinding Proposal is To Acquire Allfunds at EUR8.80 a Share

27 lis 2025, 15:41 UTC

Acquisitions, Mergers, Takeovers

Deutsche Boerse in Talks With Allfunds on Possible Acquisition

27 lis 2025, 15:11 UTC

Market Talk

Dollar Could Fall in 2026 as U.S. Rate Cuts Bite -- Market Talk

27 lis 2025, 14:26 UTC

Market Talk

Hermes' Outperformance Gap Could Narrow -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Lack of Major Budget Surprises Don't Justify Continued Sterling Strength -- Market Talk

27 lis 2025, 14:11 UTC

Market Talk

Market Talk Roundup: Latest on U.S. Politics

27 lis 2025, 13:35 UTC

Market Talk

Richemont Looks Set to Continue Outgrowing Peers -- Market Talk

27 lis 2025, 13:33 UTC

Market Talk

Sterling's Post-Budget Gains Are Probably Over -- Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Global Equities Roundup: Market Talk

27 lis 2025, 13:22 UTC

Market Talk

Kering's Plan to Revive Gucci Needs More Clarity -- Market Talk

27 lis 2025, 13:17 UTC

Market Talk

LVMH Should Be Able to Recover Next Year -- Market Talk

27 lis 2025, 11:13 UTC

Market Talk

European Gas Prices Come Under Pressure -- Market Talk

27 lis 2025, 11:07 UTC

Earnings

Genting: Positive About Prospects Over Longer Term

27 lis 2025, 11:06 UTC

Earnings

Genting: Cautious on Near-Term Prospects of Leisure, Hospitality Industry

27 lis 2025, 11:04 UTC

Earnings

Genting: International Travel Demand Expected to Remain Resilient

27 lis 2025, 11:04 UTC

Earnings

Genting: Global Growth Expected to Remain Subdued

27 lis 2025, 11:04 UTC

Earnings

Genting: Ebitda Partly Weighed by Stronger Ringgit Vs. Singapore Dollar, British Pound, U.S. Dollar

27 lis 2025, 10:59 UTC

Earnings

Genting Bhd 3Q Net Profit Fell 86% on Year

27 lis 2025, 10:58 UTC

Earnings

Genting Bhd 3Q Rev Rose 14% on Year

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q Net MYR30.3M

27 lis 2025, 10:56 UTC

Earnings

Genting Bhd 3Q EPS MYR0.0079

Peer Comparison

Price change

Vetoquinol SA Forecast

Rating Consensus

By TipRanks

0 ratings

0

Buy

0

Hold

0

Sell

Technical Score

By Trading Central

72.6 / 75.1Support & Resistance

Short Term

Bearish Evidence

Intermediate Term

Bearish Evidence

Long Term

Bearish Evidence

Sentiment

By Acuity

168 / 374 Ranking in Healthcare

News Sentiment

Neutral

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Vetoquinol SA

Vetoquinol SA, a veterinary pharmaceutical company, designs, develops, and sells veterinary drugs and non-medicinal products in Europe, the Americas, and the Asia Pacific region. It provides products in the areas of mobility, pain, and inflammation; dermatology, hygiene, and care; anti-parasite; udder health; infectious diseases; reproduction; behavior management; internal medicine; and cardiology-nephrology for cattle, sheep, pigs, poultry, dogs, cats, and horses. The company was founded in 1933 and is headquartered in Lure, France. Vetoquinol SA is a subsidiary of Soparfin SCA.
help-icon Live chat